NLRP3 and systolic heart failure: OLT1177® has been shown to be safe in humans, and it became the first NLRP3 inhibitor to complete two human proof of concept studies, one in acute gout flares (Phase 2a) and one in stable systolic heart failure (NYHA II-III) (Phase 1b) [23,24,25].